UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 561

Sortiert nach

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Annals of oncology, 2021-02, Vol.32 (2), p.208-217

2021

Volltextzugriff (PDF)

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Annals of oncology, 2019-03, Vol.30 (3), p.397-404

2019

Volltextzugriff (PDF)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2018-07, Vol.29 (7), p.1541-1547

2018

Volltextzugriff (PDF)

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Annals of oncology, 2020-03, Vol.31 (3), p.377-386

2020

Volltextzugriff (PDF)

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Annals of oncology, 2014-12, Vol.25 (12), p.2357-2362

2014

Volltextzugriff (PDF)

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Annals of oncology, 2020-08, Vol.31 (8), p.1001-1010

2020

Volltextzugriff (PDF)

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Annals of oncology, 2018-01, Vol.29 (1), p.154-161

2018

Volltextzugriff (PDF)

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Annals of oncology, 2019-08, Vol.30 (8), p.1381-1392

2019

Volltextzugriff (PDF)

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Annals of oncology, 2017-02, Vol.28 (2), p.313-320

2017

Volltextzugriff (PDF)

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Annals of oncology, 2022-06, Vol.33 (6), p.616-627

2022

Volltextzugriff (PDF)

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers

Oncogene, 2019-04, Vol.38 (17), p.3261-3273

2019

Volltextzugriff (PDF)

Résistance aux traitements du cancer du sein (RPC 2013)

Oncologie (Paris), 2013-12, Vol.15 (12), p.688-692

2013

Volltextzugriff (PDF)

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Annals of oncology, 2018-10, Vol.29, p.viii709-viii709

2018

Volltextzugriff (PDF)

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

Annals of oncology, 2014-06, Vol.25 (6), p.1128-1136

2014

Volltextzugriff (PDF)

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

Annals of oncology, 2012-03, Vol.23 (3), p.618-624

2012

Volltextzugriff (PDF)

Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer

European journal of cancer (1990), 2017-07, Vol.79, p.72-80

2017

Volltextzugriff (PDF)

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Annals of oncology, 2024-08, Vol.35 (8), p.718-727

2024

Volltextzugriff (PDF)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

Annals of oncology, 2016-01, Vol.27 (1), p.106-113

2016

Volltextzugriff (PDF)

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Annals of oncology, 2017-03, Vol.28 (3), p.590-596

2017

Volltextzugriff (PDF)

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of oncology, 2019-11, Vol.30 (11), p.1842-1842

2019

Volltextzugriff (PDF)

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

Annals of oncology, 2016-09, Vol.27 (9), p.1725-1732

2016

Volltextzugriff (PDF)

Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up

Breast (Edinburgh), 2024-10, Vol.77, p.103776, Article 103776

2024

Volltextzugriff (PDF)

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

Annals of oncology, 2015-09, Vol.26 (9), p.1904-1910

2015

Volltextzugriff (PDF)

Characteristics of IDH-mutant gliomas with non-canonical IDH mutation

Journal of neuro-oncology, 2021, Vol.151 (2), p.279-286

2021

Volltextzugriff (PDF)

1 – 25 von 561

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(543)
Mit Volltextzugriff
(541)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(159)
Life Sciences & Biomedicine
(150)
Oncology
(130)
Humans
(129)
Female
(115)
Middle Aged
(93)
Aged
(86)
Adult
(78)
Breast Cancer
(74)
Breast Neoplasms - Drug Therapy
(62)
Tumors
(58)
Biological And Medical Sciences
(53)
Medical Sciences
(53)
Breast Neoplasms - Pathology
(49)
Life Sciences
(44)
Male
(44)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(42)
Hematology, Oncology And Palliative Medicine
(41)
Chemotherapy
(37)
Cancer
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(133)
Cancer Research
(96)
Journal Of Clinical Oncology
(73)
European Journal Of Cancer
(28)
Bulletin Du Cancer
(15)
European Journal Of Cancer Supplements
(14)
Oncologie
(14)
The Lancet Oncology
(14)
Journal Of Comparative Pathology
(13)
Esmo Open
(10)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer: randomized phase II study

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

Interactions between cancer-associated fibroblasts and tumor cells promote MCL-1 dependency in estrogen receptor-positive breast cancers

Résistance aux traitements du cancer du sein (RPC 2013)

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial

Pathological complete response after neoadjuvant chemotherapy is an independent predictive factor irrespective of simplified breast cancer intrinsic subtypes: a landmark and two-step approach analyses from the EORTC 10994/BIG 1-00 phase III trial

High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients

Prospective evaluation of serum anti-Müllerian hormone dynamics in 250 women of reproductive age treated with chemotherapy for breast cancer

Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study

Use of tamoxifene-controlled ovarian hyperstimulation for fertility preservation before breast cancer treatment: A prospective cohort study with a 5-year follow-up

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab

Characteristics of IDH-mutant gliomas with non-canonical IDH mutation

Suchergebnisse filtern